Jeppe R. Christensen

Glostrup, 2600, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Delayed transcallosal conduction to the lesioned sensorimotor cortex in multiple Sclerosis: A combined TMS 7 T-MRI study.

Delayed transcallosal conduction to the lesioned sensorimotor cortex in multiple Sclerosis: A combined TMS 7 T-MRI study.

Journal: NeuroImage. Clinical
Published: April 10, 2026

Cerebrospinal Fluid sCD27 as a Biomarker of Neuroinflammatory Disease: A Systematic Review and Meta-Analysis.

Cerebrospinal Fluid sCD27 as a Biomarker of Neuroinflammatory Disease: A Systematic Review and Meta-Analysis.

Journal: Journal of neurochemistry
Published: November 26, 2025

Prevalence of tick-borne neoehrlichia mikurensis in individuals undergoing B-cell depleting therapy in Denmark: A prospective cohort study 2023-2024.

Prevalence of tick-borne neoehrlichia mikurensis in individuals undergoing B-cell depleting therapy in Denmark: A prospective cohort study 2023-2024.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: July 28, 2025

Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies.

Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies.

Journal: Clinical immunology (Orlando, Fla.)
Published: July 25, 2025

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Journal: Multiple sclerosis and related disorders
Published: July 07, 2025

Choroid plexus volume in brain disorders: a systematic review.

Choroid plexus volume in brain disorders: a systematic review.

Journal: Fluids and barriers of the CNS
Published: July 02, 2025

Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)-an individual participant data meta-analysis.

Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)-an individual participant data meta-analysis.

Journal: Multiple sclerosis and related disorders
Published: May 12, 2025

Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.

Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.

Journal: Journal of neuroimmunology
Published: April 08, 2025

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis.

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis.

Journal: European journal of neurology
Published: March 26, 2025

Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.

Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 05, 2024

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial.

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial.

Journal: BMJ open
Published: August 17, 2024

Predictors of treatment switching in the Big Multiple Sclerosis Data Network.

Predictors of treatment switching in the Big Multiple Sclerosis Data Network.

Journal: Frontiers in neurology
Published: August 07, 2023
Showing 1-12 of 26

Last Updated: 09/26/2026